Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 92,191 shares at $41.85 ($3.9M) on 2021-11-01, disclosed to the SEC on 2021-11-03.
Open-market sale of $3.9M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.85 | 4,599 | $192K | 5.0% |
| 2 | $41.85 | 4,599 | $192K | 5.0% |
| 3 | $41.85 | 7,057 | $295K | 7.6% |
| 4 | $41.85 | 7,057 | $295K | 7.6% |
| 5 | $42.43 | 7,350 | $312K | 8.0% |
| 6 | $42.43 | 7,350 |
| $312K |
| 8.0% |
| 7 | $42.43 | 4,797 | $204K | 5.2% |
| 8 | $42.43 | 4,797 | $204K | 5.2% |
| 9 | $42.10 | 2,120 | $89K | 2.3% |
| 10 | $42.10 | 3,252 | $137K | 3.5% |
| 11 | $42.10 | 3,252 | $137K | 3.5% |
| 12 | $43.04 | 991 | $43K | 1.1% |
| 13 | $43.04 | 1,518 | $65K | 1.7% |
| 14 | $43.04 | 1,518 | $65K | 1.7% |
| 15 | $41.65 | 6,067 | $253K | 6.5% |
| 16 | $41.65 | 3,957 | $165K | 4.2% |
| 17 | $41.65 | 3,957 | $165K | 4.2% |
| 18 | $41.65 | 6,067 | $253K | 6.5% |
| 19 | $42.45 | 2,346 | $100K | 2.6% |
| 20 | $42.45 | 2,346 | $100K | 2.6% |
| 21 | $42.45 | 3,597 | $153K | 3.9% |
| 22 | $42.45 | 3,597 | $153K | 3.9% |
| Total | $42.11 avg | 92,191 | $3.9M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-10-21 | $598K | — | Filing → |